Draft Brexit agreement shows progress, industry groups say

The employers’ organisation the CBI, the BioIndustry Association and the Association of the British Pharmaceutical Industry have welcomed the progress made in securing a Brexit deal, but said more clarity was needed.

The ABPI, which represents 150 biopharmaceutical companies, described the draft agreement as “an important step towards securing a Brexit deal”.

“Agreeing a transition period will mean that our members can continue to supply medicines to patients without delay or disruption come March 2019,” Mike Thompson, ABPI’s chief executive, said on 15 November. He added that there was “more work to be done”.